Decipher® Predicts Metastasis and Identifies Prostate Cancer Biomarkers in African American Men

September 1, 2015
Decipher® Predicts Metastasis and Identifies Prostate Cancer Biomarkers in African American Men
A genomic marker panel was recently described that has the ability to predict tumor aggressiveness in a race-dependent manner. [iStock/gchutka]

GenomeDx Biosciences reported that its commercially available Decipher® testing platform identified, with statistical significance, a set of prostate cancer biomarkers predictive of aggressive disease in African American men after radical prostate surgery. This represents the first and only study describing a set of genomic markers that have the ability to predict tumor aggressiveness in a race-dependent manner, said Elai Davicioni, Ph.D., president and CSO at GenomeDx and an author on a study (“Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer”), that was published online in the Journal of Clinical Oncology.

Additionally, the study demonstrated that the Medicare-covered Decipher test is an independent predictor of metastasis in African American men.

For the rest of the story, click here.